Home › Multiple Sclerosis › NCT05170126
A Study on the Safety of Ozanimod Exposure in Pregnant Women and Their Offspring
ZEPOSIA® (Ozanimod) Pregnancy Registry: A Prospective, Observational Study on the Safety of Ozanimod Exposure in Pregnant Women and Their Offspring
Who can join
All ages · Women
Full eligibility criteria
Inclusion Criteria: * Diagnosis of Multiple sclerosis (MS) * Currently or recently pregnant * Reside in the United States, Canada or Germany. Exclusion Criteria: • Exposure to other S1P therapies, cladribine, or mitoxantrone during the first trimester. Other protocol-defined inclusion/exclusion criteria apply
About the study
The purpose of this study is to provide information on maternal, fetal, and infant outcomes following exposure of ozanimod during pregnancy so that participants and physicians can weigh the benefits and risks of exposure to the pharmaceutical during pregnancy and make informed treatment decisions.
Sponsor: Bristol-Myers Squibb · Participants: 1,182 · Started: Jul 15, 2022
Contact the study team
- BMS Study Connect Contact Center www.BMSStudyConnect.com · Phone: 855-907-3286
Official record on ClinicalTrials.gov — NCT05170126
Locations in the U.S.
| Maryland | Evidera, Bethesda Evidera INC., Bethesda |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.